The approval marks Lupin’s first product entry into the Chinese market, representing a development in the company’s global expansion plans.
Oseltamivir Phosphate for oral suspension, 6 mg/mL, will be launched and commercialised in China to expand access to influenza treatment and prevention, particularly for paediatric use.
Lupin said the approval reinforces its commitment to delivering high-quality and affordable medicines to patients and children in need.
The oral suspension is indicated for the treatment of influenza A and B in patients aged two weeks and older, and for the prevention of influenza A and B in individuals aged one year and above.
Fabrice Egros, President – Corporate Development, Lupin, said, “We are delighted that we have received approval for Oseltamivir Oral Suspension in China. This is a strategic step in our entry into one of the world’s largest pharmaceutical markets.”
He added that it reflects their shared commitment to expanding access to high-quality, affordable therapies, particularly in paediatric care.
Also Read: Pharma, healthcare stocks drag markets amid volatility; Nifty and Sensex close week in green
Wei Ren, President, Yabao, said, “We are pleased to announce the official approval of Oseltamivir Oral Suspension in China, marking a key milestone in our partnership with Lupin. It reinforces Yabao’s dedication to quality paediatric medicines and showcases our strong collaboration. We will further expand our R&D portfolio for paediatric and adult chronic disease drugs to jointly advance our businesses.”
Lupin Limited shares ended lower on Friday at ₹2,270.70 on the NSE, down ₹13.80 or 0.60% from the previous close.
Also Read: RBI approves record ₹2.86 lakh crore dividend transfer to centre for FY26
